A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502845-83-00

Acronym

CRD-4730-201

Enrollment

Registered

2024-03-14

Start date

2024-04-15

Completion date

2025-05-31

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Brief summary

Adverse events, clinical laboratory test results (hematology, serum chemistry, and urinalysis), vital sign measurements, and 12-lead electrocardiogram (ECG) results, and physical examination findings

Detailed description

Change in ventricular arrhythmia (VA) score from baseline to Day 1, from baseline to Day 8, and from baseline to Day 15, Plasma concentrations of CRD-4730 over time for each treatment period

Interventions

DRUGCRD-4730

DRUGEncapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Adverse events, clinical laboratory test results (hematology, serum chemistry, and urinalysis), vital sign measurements, and 12-lead electrocardiogram (ECG) results, and physical examination findings	—

Secondary

Measure	Time frame
Change in ventricular arrhythmia (VA) score from baseline to Day 1, from baseline to Day 8, and from baseline to Day 15, Plasma concentrations of CRD-4730 over time for each treatment period	—

Countries

France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026